Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death
Emily Truong, Jeffrey Gornbein, Ju Dong Yang, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 10, pp. 2570-2577.e1
Closed Access | Times Cited: 22

Showing 22 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 296
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Monica A. Tincopa, Rohit Loomba
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 660-670
Closed Access | Times Cited: 84
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 56
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 48
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 44
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
Mazen Noureddin, Michael Charlton, Stephen A. Harrison, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 12, pp. 2367-2377
Open Access | Times Cited: 25
NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Geladari, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 826-826
Open Access | Times Cited: 12
Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease
Nabil Noureddin, Nedret Copur‐Dahi, Rohit Loomba
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Closed Access | Times Cited: 12
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 1
Plasma FSTL-1 as a non-invasive diagnostic biomarker for patients with advanced liver fibrosis
Wenzhu Li, Yongquan Chi, Xuan Xiao, et al.
Hepatology (2024)
Open Access | Times Cited: 5
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
Yue Wang, Sherlot Juan Song, Yichong Jiang, et al.
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 4
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis
Sheena Bhushan, Aalam Sohal, Mazen Noureddin, et al.
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography
Mădălina-Gabriela Țâru, Monica Lupșor‐Platon
Cancers (2023) Vol. 15, Iss. 16, pp. 4097-4097
Open Access | Times Cited: 9
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
Wah‐Kheong Chan, Salvatore Petta, Mazen Noureddin, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 3
Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques
David Hudson, Tamoor Afzaal, Hasan Bualbanat, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 3
Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
Feryal Savari, Seyed Ali Mard
Heliyon (2024) Vol. 10, Iss. 7, pp. e28468-e28468
Open Access | Times Cited: 2
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
Angelo Armandi, Maurice Stephan Michel, Kamela Gjini, et al.
Expert Review of Molecular Diagnostics (2023) Vol. 23, Iss. 9, pp. 771-782
Closed Access | Times Cited: 5
A PRAGMATIC MANAGEMENT APPROACH FOR METABOLIC DYSFUNCTION ASSOCIATED STEATOSIS AND STEATOHEPATITIS
Neha Shah, Arun J. Sanyal
The American Journal of Gastroenterology (2024)
Closed Access | Times Cited: 1
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Lynna Alnimer, Mazen Noureddin
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 394-397
Open Access | Times Cited: 2
Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review
Kyaw Min Tun, Nabil Noureddin, Mazen Noureddin
Clinical Liver Disease (2023) Vol. 22, Iss. 3, pp. 103-112
Open Access | Times Cited: 2
Positron emission tomography combined with serum biomarkers detects fibrotic MASH
Sean Romeo, Connie Chan, Karen Matsukuma, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Comparison of the magnetic resonance elastography and FIB-4 (MEFIB) Index and vibration-controlled transient elastography for significant metabolic dysfunction–associated steatotic liver disease fibrosis
Chinmay Bera, Mina Fakhriyehasl, N Perez, et al.
Canadian Liver Journal (2024) Vol. 7, Iss. 4, pp. 419-426
Closed Access
Page 1

Scroll to top